{"id":"ten-days-oseltamivir","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"2","effect":"Headache"},{"rate":"5","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1229","moleculeType":"Small molecule","molecularWeight":"312.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir inhibits viral neuraminidase, an enzyme on the surface of influenza viruses that cleaves sialic acid receptors and allows newly formed virus particles to escape from infected cells. By blocking this enzyme, the drug prevents viral release and transmission to neighboring cells, thereby reducing viral load and shortening the duration of infection. The 10-day regimen represents an extended treatment course compared to standard 5-day dosing.","oneSentence":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:56.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza A and B infection treatment"},{"name":"Influenza prophylaxis"}]},"trialDetails":[{"nctId":"NCT07496736","phase":"PHASE3","title":"Post-exposure Influenza Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-12-01","conditions":"Influenza","enrollment":200},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT02469298","phase":"PHASE2","title":"Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-01","conditions":"Virus Diseases","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ten-days oseltamivir","genericName":"Ten-days oseltamivir","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread. Used for Influenza A and B infection treatment, Influenza prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}